10-Q: MIRA Pharmaceuticals Reports Second Quarter 2024 Financial Results, Cites Ongoing Development of Novel Drug Candidates

MIRA Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting ongoing research and development efforts for its drug candidates, Ketamir-2 and MIRA-55.

Summary

• MIRA Pharmaceuticals, a pre-clinical-stage company, released its financial results for the quarter ended June 30, 2024.
• The company is focused on developing two neuroscience programs, Ketamir-2 and MIRA-55, targeting neurological and neuropsychiatric disorders.
• MIRA reported a net loss of $1.69 million for the three months ended June 30, 2024, and a net loss of $3.41 million for the six months ended June 30, 2024.
• Research and development expenses were $0.6 million for the three months and $1.4 million for the six months ended June 30, 2024, primarily related to pre-clinical research for Ketamir-2.
• General and administrative expenses were $1.1 million for the three months and $2.1 million for the six months ended June 30, 2024.
• The company had cash of approximately $2.8 million as of June 30, 2024, and used approximately $1.9 million in operations during the six months ended June 30, 2024.
• MIRA expects to fund operations through the fourth quarter of 2024 with available borrowings from a related-party loan.
• The company has identified a novel and improved version of its molecule, MIRA-55, which is now its lead compound for its oral pharmaceutical marijuana drug candidate.
• MIRA has filed a provisional patent for MIRA-55, which encompasses all pre-clinical studies.
• The company's ability to continue as a going concern is dependent on obtaining additional external funding.

Sentiment

Score: 4

Explanation: The document highlights positive developments in drug discovery but also reveals significant financial challenges and risks, including the need for additional funding and ineffective disclosure controls. The sentiment is cautiously negative due to the financial situation and going concern issues.

Positives

• The company has identified an improved version of its molecule, MIRA-55, which is now the lead compound.
• MIRA has filed a provisional patent for MIRA-55, potentially securing intellectual property rights.
• The DEA has concluded that neither Ketamir-2 nor MIRA-55 are controlled substances, which could simplify regulatory pathways.
• The company has made initial payments for pre-clinical research projects for Ketamir-2.
• MIRA has a related-party loan agreement in place to help fund operations through the fourth quarter of 2024.

Negatives

• The company reported a net loss of $1.69 million for the three months and $3.41 million for the six months ended June 30, 2024.
• MIRA used approximately $1.9 million of cash in operations during the six months ended June 30, 2024.
• The company's ability to continue as a going concern is dependent on obtaining additional external funding.
• The company's disclosure controls and procedures were not effective as of June 30, 2024.
• MIRA has incurred significant losses since its inception.

Risks

• The company's ability to fund ongoing operations and future pre-clinical and clinical trials is dependent on obtaining significant additional external funding.
• There is no assurance that any fundraising will be achieved on commercially reasonable terms.
• The company expects to continue to generate losses in the foreseeable future.
• MIRA relies on third parties for pre-clinical trials, which could lead to delays or failures.
• The company's engagement with foreign vendors may be subject to new U.S. legislation or investigations.
• The company's disclosure controls and procedures were not effective as of June 30, 2024.
• The company does not have sufficient cash to support operations for at least the next 12 months.

Future Outlook

The company expects to fund operations through the fourth quarter of 2024 with available borrowings from a related-party loan and will require additional financing and equity raises to fund its operations, to continue and complete pre-clinical and clinical development activities and to commercially develop and ultimately launch its product candidates. The company expects to continue to generate losses in the foreseeable future.

Management Comments

• Management believes that the enhancements to internal controls will be sufficient to remediate previously identified material weaknesses.
• Management does not expect that the disclosure controls and procedures or internal control over financial reporting will necessarily prevent all fraud and material error.

Industry Context

MIRA Pharmaceuticals is operating in the competitive pharmaceutical industry, focusing on developing novel treatments for neurological and neuropsychiatric disorders. The company's focus on oral drug delivery and non-controlled substances aligns with current trends in the industry.

Comparison to Industry Standards

• MIRA's financial results are typical for a pre-clinical-stage pharmaceutical company, with significant losses due to research and development expenses.
• Companies like Cassava Sciences (SAVA) and Anavex Life Sciences (AVXL), which are also developing treatments for neurological disorders, have similar high R&D costs and net losses in their early stages.
• MIRA's reliance on related-party funding is not uncommon for early-stage biotech companies, but it also introduces additional risks.
• The discovery of MIRA-55 and the filing of a provisional patent are positive developments, but the company still faces significant challenges in obtaining regulatory approval and commercializing its products.
• Compared to companies with approved products, MIRA's financial metrics are significantly different, as it is still in the pre-clinical stage and has no revenue.

Related Party Transactions

• The company has a license agreement with MIRALOGX, a related party, for Ketamir-2.
• MIRA has a loan agreement with MIRALOGX, a related party.
• The company has shared management and lease costs with related parties.
• The company paid payables on behalf of a related party in the amount of $0.024 million.
• The company incurred $0.010 million in costs related to shared management with related parties.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity raises.
• Employees may be impacted by the company's financial instability.
• Customers and suppliers are not directly impacted at this pre-clinical stage.
• Creditors face the risk of non-payment if the company fails to secure additional funding.

Next Steps

• The company will continue pre-clinical research and development of Ketamir-2 and MIRA-55.
• MIRA will seek additional funding to support its operations and clinical trials.
• The company will work to improve its internal controls over financial reporting.
• MIRA will monitor the potential impact of new U.S. legislation or investigations on its foreign vendors.

Key Dates

Keywords

MIRA Pharmaceuticals, Ketamir-2, MIRA-55, pharmaceutical development, pre-clinical trials, neuroscience, neurologic disorders, neuropsychiatric disorders, antidepressant, oral ketamine analog, oral pharmaceutical marijuana, FDA approval, financial results, going concern, related party loan